Skip to content
Study details
Enrolling now

Gemcitabine and Nab-Paclitaxel Infusion Schedule for Metastatic Pancreatic Cancer

Anne Noonan
NCT IDNCT04115163ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

53

Study length

about 5.5 years

Ages

18+

Locations

1 site in OH

What this study is about

This trial is testing a new way to give gemcitabine and nab-paclitaxel, two chemotherapy drugs, to people with pancreatic cancer that has spread. The goal is to see if this schedule improves how well the treatment works.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Gemcitabine
  • 2.Take Nab-paclitaxel

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Injection / IVInjection / IV

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

gemcitabine, paclitaxel (Taxane chemotherapy; stabilizes microtubules)

Drug routes

injection (Injection), infusion

Endpoints

Primary: Overall response rate (ORR)

Secondary: Disease control rate, Incidence of adverse events (AEs), Overall survival (OS), Progression-free survival (PFS)

Body systems

Oncology